{"log_id": 8843073975765552330, "direction": 0, "words_result_num": 67, "words_result": [{"probability": {"variance": 0.012947, "average": 0.935408, "min": 0.547408}, "location": {"width": 888, "top": 40, "height": 66, "left": 111}, "words": "国外交献报道,197例65岁以上的老年患老进行了临床试验,在安全性及有效性方面,与青壮年患者没有显著性差"}, {"probability": {"variance": 0.016536, "average": 0.940049, "min": 0.515612}, "location": {"width": 519, "top": 82, "height": 48, "left": 70}, "words": "别。由于在老年惠者中通常易发生感染,因此在治疗中应予以注意"}, {"probability": {"variance": 7e-06, "average": 0.997231, "min": 0.991327}, "location": {"width": 130, "top": 124, "height": 28, "left": 72}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.004213, "average": 0.97034, "min": 0.740339}, "location": {"width": 270, "top": 137, "height": 36, "left": 114}, "words": "目前尚元明确的药物相互作用资料"}, {"probability": {"variance": 0.023832, "average": 0.926499, "min": 0.38517}, "location": {"width": 891, "top": 151, "height": 68, "left": 113}, "words": "人对TNFR:Fc的最大耐受剂尚未确定。国外文就报道,在对健康志愿者进行的内毒素血症研究中,以单量"}, {"probability": {"variance": 1.7e-05, "average": 0.99386, "min": 0.98974}, "location": {"width": 78, "top": 174, "height": 20, "left": 77}, "words": "【药物过量"}, {"probability": {"variance": 0.010454, "average": 0.946348, "min": 0.552465}, "location": {"width": 927, "top": 175, "height": 68, "left": 78}, "words": "60mgm静脉注射未见剂最限制的毒性,在一组美风湿关节炎临床试验中,一位患者误用 HTNFR:Fc62mg/m每周两"}, {"probability": {"variance": 0.020482, "average": 0.920042, "min": 0.412636}, "location": {"width": 351, "top": 225, "height": 40, "left": 78}, "words": "次皮下注射,连续3,并未见不良反应发生"}, {"probability": {"variance": 0.01137, "average": 0.955569, "min": 0.447961}, "location": {"width": 891, "top": 241, "height": 67, "left": 114}, "words": "在238例中,重度活动性类风湿性关节炎患者参加的随机双育,甲氨蝶脸对照,多中心临床研究中,患者接受了24"}, {"probability": {"variance": 7.9e-05, "average": 0.992949, "min": 0.975652}, "location": {"width": 84, "top": 262, "height": 24, "left": 78}, "words": "【临床试验"}, {"probability": {"variance": 0.023314, "average": 0.914018, "min": 0.454106}, "location": {"width": 929, "top": 264, "height": 68, "left": 81}, "words": "周的治疗,其中试验组接觉益赛普25mg天,每周2次皮下注射治疗一对照维接受目服甲氨蝶玲治疗:疗效评价采用"}, {"probability": {"variance": 0.013586, "average": 0.920548, "min": 0.592709}, "location": {"width": 929, "top": 287, "height": 66, "left": 82}, "words": "ACR20/5070疗效评定标准,结果显示,在治疗2周后益赛普组ACR20有效率为35.59%,疗效明显优于对照组"}, {"probability": {"variance": 0.018258, "average": 0.915275, "min": 0.431535}, "location": {"width": 922, "top": 309, "height": 66, "left": 88}, "words": "P0.05)治疗12周后,益赛普组ACR20有效率为66.10%疗效明显优于对照组(P0.053治疗24周后,益赛普"}, {"probability": {"variance": 0.032239, "average": 0.86555, "min": 0.353247}, "location": {"width": 929, "top": 331, "height": 67, "left": 82}, "words": "组AGR20有效率为80.39‰,ACR70有效率达优于对照组1P0.05月主的药物不良反应有注射部位反应,皮疹、转"}, {"probability": {"variance": 0.002451, "average": 0.971407, "min": 0.821245}, "location": {"width": 484, "top": 374, "height": 47, "left": 83}, "words": "氨酶升高,感染等,感染发生率在两组中比较没有显著性差异"}, {"probability": {"variance": 0.01108, "average": 0.94718, "min": 0.426267}, "location": {"width": 893, "top": 375, "height": 66, "left": 120}, "words": "在144例宁,重度斑块状银屑病患者参加的随机双育、甲氨蝶对照,多中心临床研究中,患者接受了12周的治"}, {"probability": {"variance": 0.00614, "average": 0.962818, "min": 0.654133}, "location": {"width": 909, "top": 399, "height": 66, "left": 85}, "words": "疗,其中试验组接受益赛普25mg次,每周2次皮下注射治疗,对照接受口服甲氨蝶吟治疗疗效评价采用PASI"}, {"probability": {"variance": 0.013445, "average": 0.945656, "min": 0.471952}, "location": {"width": 930, "top": 420, "height": 66, "left": 85}, "words": "PGA、DLQl患者对病情整体评分,疗分析采用PAS107590评分,结果显示,从第4周开始益赛普的治疗效果明显"}, {"probability": {"variance": 0.00917, "average": 0.94818, "min": 0.558614}, "location": {"width": 740, "top": 450, "height": 60, "left": 87}, "words": "优于对照组到治疗第12周时,益舞普组的患者达到PAS15017590的比例为:93.3383.3"}, {"probability": {"variance": 0.001333, "average": 0.965617, "min": 0.88571}, "location": {"width": 151, "top": 443, "height": 28, "left": 865}, "words": "56.67疗效明显"}, {"probability": {"variance": 0.023584, "average": 0.892851, "min": 0.429062}, "location": {"width": 167, "top": 501, "height": 31, "left": 89}, "words": "优于对照组(P0.05"}, {"probability": {"variance": 0.013632, "average": 0.946555, "min": 0.374362}, "location": {"width": 726, "top": 464, "height": 59, "left": 291}, "words": "治疗12周后,患者对益赛都能很好的耐受,不良反应发生宰低,程度轻,和对照组比较没"}, {"probability": {"variance": 0.012899, "average": 0.955783, "min": 0.385056}, "location": {"width": 893, "top": 509, "height": 65, "left": 126}, "words": "在141例活动性强直性脊柱炎患者参加的随机双育、安慰剂对照,多中心的临床研究中,患者接受12周的治疗其"}, {"probability": {"variance": 0.01096, "average": 0.942934, "min": 0.515423}, "location": {"width": 928, "top": 532, "height": 66, "left": 92}, "words": "中分为2个阶段:在前6周的双有对照治疗价段试验组患者接受益赛普25m1次,每周2次皮下注射,对照组使用支慰"}, {"probability": {"variance": 9e-06, "average": 0.997726, "min": 0.993531}, "location": {"width": 53, "top": 532, "height": 20, "left": 90}, "words": "有差异"}, {"probability": {"variance": 0.015544, "average": 0.929987, "min": 0.459139}, "location": {"width": 930, "top": 552, "height": 70, "left": 92}, "words": "剂。该阶段结束后进人后6周开旅治疗阶段,两组都使用益赛普、药量同上、疗效评价采用ASAS20评价标准。结果显"}, {"probability": {"variance": 0.014648, "average": 0.940179, "min": 0.38136}, "location": {"width": 891, "top": 577, "height": 67, "left": 93}, "words": "示,在双育对照阶段治疗2周和6周时益赛普组ASAS20的比例为55.079和68.12%,明显优于安慰组(P0.001"}, {"probability": {"variance": 0.010778, "average": 0.958021, "min": 0.474527}, "location": {"width": 928, "top": 597, "height": 68, "left": 94}, "words": "益赛普连续治疗12周时达到ASAS20的比例是78.269。安慰剂组在开放期经过6周益赛普治疗后,达到ASAS20的比例"}, {"probability": {"variance": 0.012321, "average": 0.942712, "min": 0.497632}, "location": {"width": 927, "top": 619, "height": 69, "left": 96}, "words": "是75%疗效明星,研究中患者对益赛普都能很好的耐受一在双育对照阶段,益赛普不良反应发生率和安慰剂比较无显"}, {"probability": {"variance": 0.035025, "average": 0.896836, "min": 0.405165}, "location": {"width": 517, "top": 663, "height": 47, "left": 96}, "words": "著姜异。发生的不良反应程度轻个需要特别治疗,可以自行复"}, {"probability": {"variance": 5.4e-05, "average": 0.994291, "min": 0.980139}, "location": {"width": 86, "top": 705, "height": 28, "left": 106}, "words": "药理毒理】"}, {"probability": {"variance": 0.023224, "average": 0.922205, "min": 0.359161}, "location": {"width": 890, "top": 707, "height": 68, "left": 140}, "words": "已知肿坏死因于(TNF-4)是类风湿性关节炎、银屑病、强直性脊炎等病理过程中的一个主要炎性介质,其参与调"}, {"probability": {"variance": 2e-06, "average": 0.998183, "min": 0.996397}, "location": {"width": 74, "top": 731, "height": 22, "left": 99}, "words": "药理作用"}, {"probability": {"variance": 0.010118, "average": 0.943849, "min": 0.574813}, "location": {"width": 912, "top": 732, "height": 66, "left": 100}, "words": "控的炎症反应可导致美节的病理改变本品的作用机制为竞争性地与血中TNF-α结合,阻断它和细肥表面TNF受体结合"}, {"probability": {"variance": 0.05322, "average": 0.836252, "min": 0.38556}, "location": {"width": 91, "top": 795, "height": 26, "left": 101}, "words": "降低其性"}, {"probability": {"variance": 0.007857, "average": 0.946979, "min": 0.676037}, "location": {"width": 598, "top": 810, "height": 54, "left": 144}, "words": "急性毒性试验结果显示给予小鼠静脉注射160mgkg的益赛著,未见毒性反应"}, {"probability": {"variance": 1e-06, "average": 0.998906, "min": 0.997061}, "location": {"width": 73, "top": 820, "height": 21, "left": 102}, "words": "毒理研究"}, {"probability": {"variance": 0.004003, "average": 0.954478, "min": 0.737754}, "location": {"width": 615, "top": 833, "height": 54, "left": 144}, "words": "给予猴4周的长期毒性试验结果显示15mgkg剂量的益赛普,无明星毒性反应"}, {"probability": {"variance": 0.01996, "average": 0.926748, "min": 0.45709}, "location": {"width": 869, "top": 863, "height": 68, "left": 148}, "words": "临床研究表明,重组人Ⅱ型肿癣坏死因子受体一抗体能台蛋白经皮下注射后,在注射部位缓慢收,羊次给药后"}, {"probability": {"variance": 9.3e-05, "average": 0.992803, "min": 0.971042}, "location": {"width": 113, "top": 883, "height": 27, "left": 103}, "words": "【药代动力学】"}, {"probability": {"variance": 0.012503, "average": 0.943339, "min": 0.465904}, "location": {"width": 928, "top": 886, "height": 69, "left": 107}, "words": "约48小时后可达血药浓度峰值,绝对生物利用度约为76%。每周给药2次,达稳态时的血药浓度约为单次给药峰浓度的"}, {"probability": {"variance": 0.018599, "average": 0.911881, "min": 0.436351}, "location": {"width": 863, "top": 931, "height": 66, "left": 154}, "words": "11名活动性类风湿关节炎患者皮下注射25m次,每周2次,连续给药6周后,由TNFR:Fc达稳态的时间为40E"}, {"probability": {"variance": 0.021142, "average": 0.892596, "min": 0.486138}, "location": {"width": 924, "top": 953, "height": 68, "left": 112}, "words": "20h.达稳态时峰浓度(C导max为3.0±2ugmt,达稳态时谷浓度( Css) min为2t02pg/ml.平均稳态浓度Css"}, {"probability": {"variance": 8e-06, "average": 0.997079, "min": 0.994278}, "location": {"width": 30, "top": 956, "height": 19, "left": 108}, "words": "2倍"}, {"probability": {"variance": 0.024618, "average": 0.877101, "min": 0.463324}, "location": {"width": 745, "top": 984, "height": 60, "left": 113}, "words": "为2.g±0.3g/ml波动系数为12.8上3.3%最后一次绘药后TNFR:Fc的半衰期T1e为74±4h"}, {"probability": {"variance": 0.041398, "average": 0.859664, "min": 0.420997}, "location": {"width": 112, "top": 976, "height": 26, "left": 923}, "words": "为53±6h.c"}, {"probability": {"variance": 0.019912, "average": 0.942008, "min": 0.395385}, "location": {"width": 889, "top": 1017, "height": 69, "left": 153}, "words": "在健康人和急性肾脏或肝脏能异常的病人中观察到的血药浓度没有十分显著的差别、因此,对于脏功能受损"}, {"probability": {"variance": 0.033138, "average": 0.912427, "min": 0.409047}, "location": {"width": 149, "top": 1036, "height": 29, "left": 114}, "words": "为102.8±10.4m/h"}, {"probability": {"variance": 0.021604, "average": 0.918645, "min": 0.419778}, "location": {"width": 730, "top": 1049, "height": 59, "left": 117}, "words": "的病人无需调整剂量,在研餐中未观察到甲氨蝶呤MTX对 THTNFR:Fc的药代动力学有影响"}, {"probability": {"variance": 0.00142, "average": 0.925571, "min": 0.873234}, "location": {"width": 57, "top": 1108, "height": 18, "left": 115}, "words": "【贮藏"}, {"probability": {"variance": 0.028279, "average": 0.909978, "min": 0.453594}, "location": {"width": 377, "top": 1107, "height": 42, "left": 157}, "words": "本品应置于2-8℃,避光干燥保存和运不可冷冻"}, {"probability": {"variance": 4e-06, "average": 0.99878, "min": 0.995396}, "location": {"width": 59, "top": 1150, "height": 20, "left": 115}, "words": "【包装】"}, {"probability": {"variance": 0.025216, "average": 0.908611, "min": 0.456657}, "location": {"width": 402, "top": 1148, "height": 45, "left": 158}, "words": "2毫升西林瓶翻硅玻璃管制注射剂瓶装),1支/盒"}, {"probability": {"variance": 0.000295, "average": 0.990053, "min": 0.955735}, "location": {"width": 72, "top": 1193, "height": 20, "left": 120}, "words": "【有效期】"}, {"probability": {"variance": 2e-06, "average": 0.998234, "min": 0.996671}, "location": {"width": 53, "top": 1213, "height": 19, "left": 163}, "words": "36个月"}, {"probability": {"variance": 0.00099, "average": 0.982827, "min": 0.920026}, "location": {"width": 94, "top": 1235, "height": 22, "left": 119}, "words": "执行标准】"}, {"probability": {"variance": 0.009185, "average": 0.935781, "min": 0.70633}, "location": {"width": 103, "top": 1253, "height": 23, "left": 174}, "words": "BS00152007"}, {"probability": {"variance": 0.009904, "average": 0.936347, "min": 0.729954}, "location": {"width": 93, "top": 1278, "height": 22, "left": 121}, "words": "【批准文号】"}, {"probability": {"variance": 0.011318, "average": 0.949681, "min": 0.587856}, "location": {"width": 344, "top": 1282, "height": 39, "left": 165}, "words": "国药准字S20050058和国药准字S20050059"}, {"probability": {"variance": 7e-06, "average": 0.997626, "min": 0.992873}, "location": {"width": 94, "top": 1320, "height": 23, "left": 122}, "words": "【生产企业"}, {"probability": {"variance": 0.013381, "average": 0.958578, "min": 0.504853}, "location": {"width": 340, "top": 1325, "height": 41, "left": 165}, "words": "企业名称:上海中信保药业投份有限公司"}, {"probability": {"variance": 0.007542, "average": 0.965383, "min": 0.592592}, "location": {"width": 441, "top": 1342, "height": 44, "left": 167}, "words": "生产地址:上海市浦东新区张江高科技园区李泳路399号"}, {"probability": {"variance": 0.002449, "average": 0.971382, "min": 0.844892}, "location": {"width": 151, "top": 1378, "height": 30, "left": 167}, "words": "邮玫编码:201203"}, {"probability": {"variance": 0.002364, "average": 0.977424, "min": 0.744681}, "location": {"width": 384, "top": 1386, "height": 44, "left": 168}, "words": "电话和传真号码:021-50791399:021-585535"}, {"probability": {"variance": 1.3e-05, "average": 0.997411, "min": 0.982301}, "location": {"width": 400, "top": 1411, "height": 40, "left": 168}, "words": "全国免费咨询电话:80082081704008208170"}, {"probability": {"variance": 0.002351, "average": 0.969523, "min": 0.873213}, "location": {"width": 71, "top": 1453, "height": 20, "left": 171}, "words": "网址:ht"}, {"probability": {"variance": 0.000343, "average": 0.986903, "min": 0.960709}, "location": {"width": 125, "top": 1442, "height": 27, "left": 312}, "words": " cpgi-pharm. com"}], "language": 3}